Cotización InflaRx NV - IFRX

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

2.50

Postura de Compra

1.49

Postura de Venta

2.76

Volume Operado de la Acción

0.00 Rango del Día 0.00

1.165 Rango de 52 semanas 2.815

Capitalización de Mercado [m]

147.208M

Precio Anterior

2.50

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

301,970

Acciones en circulación

58,883,272

Rendimiento del Dividendo

Ratio Precio/Utilidad

-3.45

Beneficio por acción (BPA)

-0.72

turnover

63k

Beneficio neto

-42.67M

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.inflarx.de

Sede

Jena, Deu

Fundado

InflaRx NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IFRX. The last closing price for InflaRx NV was US$2.50. Over the last year, InflaRx NV shares have traded in a share price range of US$ 1.165 to US$ 2.815.

InflaRx NV currently has 58,883,272 shares in issue. The market capitalisation of InflaRx NV is US$147.21 million. InflaRx NV has a price to earnings ratio (PE ratio) of -3.45.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

InflaRx Announces Participation in January Events in San Francisco

JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the...

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.03	-1.18577075099	2.53	2.65	2.28	194968	2.51133941	CS
4	-0.02	-0.793650793651	2.52	2.76	2.16	183715	2.47195097	CS
12	0.95	61.2903225806	1.55	2.815	1.48	301970	2.24396602	CS
26	0.99	65.5629139073	1.51	2.815	1.23	170703	2.07564512	CS
52	0.85	51.5151515152	1.65	2.815	1.165	179276	1.79547715	CS
156	-0.73	-22.600619195	3.23	6.15	0.7762	291759	2.76187196	CS
260	-0.9	-26.4705882353	3.4	9.7	0.7762	519189	3.98232083	CS

IFRX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de InflaRx NV?

El precio actual de las acciones de InflaRx NV es US$ 2.50

¿Cuántas acciones de InflaRx NV están en circulación?

InflaRx NV tiene 58,883,272 acciones en circulación

¿Cuál es la capitalización de mercado de InflaRx NV?

La capitalización de mercado de InflaRx NV es USD 147.21M

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de InflaRx NV?

InflaRx NV ha negociado en un rango de US$ 1.165 a US$ 2.815 durante el último año

¿Cuál es el ratio PE (precio/beneficio) de InflaRx NV?

El ratio precio/beneficio de InflaRx NV es -3.45

¿Cuál es el ratio de efectivo a ventas de InflaRx NV?

El ratio de efectivo a ventas de InflaRx NV es 2.27k

¿Cuál es la moneda de reporte de InflaRx NV?

InflaRx NV presenta sus resultados financieros en EUR

¿Cuál es el último ingresos anual de InflaRx NV?

El último ingresos anual de InflaRx NV es EUR 63k

¿Cuál es el último beneficio anual de InflaRx NV?

El último beneficio anual de InflaRx NV es EUR -42.67M

¿Cuál es la dirección registrada de InflaRx NV?

La dirección registrada de InflaRx NV es WINZERLAER, JENA, 07745

¿Cuál es la dirección del sitio web de InflaRx NV?

La dirección del sitio web de InflaRx NV es www.inflarx.de

¿En qué sector industrial opera InflaRx NV?

InflaRx NV opera en el sector PHARMACEUTICAL PREPARATIONS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
DGNXDiginex Ltd	17.84 (137.87%)	355.04k
FSEAFirst Seacoast Bancorp Inc	US$ 15.90 (59.00%)	6
BBGIBeasley Broadcast Group Inc	US$ 13.31 (58.45%)	14
QETAQuetta Acquisition Corporation	US$ 16.80 (58.34%)	4
CRWSCrown Crafts Inc	US$ 6.99 (56.03%)	1
GLACGlobal Lights Acquisition Corporation	US$ 5.00 (-53.27%)	201
CVBFCVB Financial Corporation	US$ 11.00 (-46.83%)	203
VIRCVirco Manufacturing Company	US$ 6.01 (-45.86%)	1
CPBICentral Plains Bancshares Inc	US$ 10.01 (-31.67%)	7
DCOMDime Community Bancshares Inc	US$ 22.00 (-30.71%)	200
KOPNKopin Corporation	US$ 2.065 (40.48%)	8.72M
HEPAHepion Pharmaceuticals Inc	US$ 0.1554 (15.11%)	4.86M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.3182 (-0.25%)	4.24M
ASSTAsset Entities Inc	US$ 1.59 (16.91%)	3.68M
SHViShares Short Treasury Bond ETF	US$ 110.375 (0.01%)	3.39M